Orris

Multiple sclerosis

Reading File
Finding Sources
Searching PubMed

"multiple sclerosis"[MeSH Terms] AND treatment

Multiple sclerosis (MS) is a broad topic. Here's a map of what it covers, a brief overview, and then I'll ask which area you want to go deep on.

Topic breakdown

  1. Epidemiology & risk factors - prevalence, latitude gradient, genetics (HLA-DRB1*15:01), EBV, vitamin D, smoking
  2. Pathophysiology - autoimmune demyelination, plaque formation, axonal loss, neurodegeneration
  3. Clinical subtypes & course - relapsing-remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS), clinically isolated syndrome (CIS), radiologically isolated syndrome (RIS)
  4. Clinical presentation - optic neuritis, sensory symptoms, Lhermitte's sign, internuclear ophthalmoplegia, transverse myelitis, fatigue, Uhthoff's phenomenon
  5. Diagnosis - McDonald criteria, MRI findings (dissemination in space/time), CSF oligoclonal bands, evoked potentials, differential diagnosis (NMOSD, MOGAD)
  6. Disease-modifying therapy (DMT) - injectables (interferons, glatiramer acetate), orals (fingolimod, dimethyl fumarate, teriflunomide, siponimod, cladribine), monoclonal antibodies (natalizumab, ocrelizumab, ofatumumab, alemtuzumab), high-efficacy vs escalation strategies
  7. Acute relapse management - high-dose corticosteroids, plasma exchange for refractory relapses
  8. Symptomatic management - spasticity, bladder dysfunction, fatigue, pain, cognitive impairment, depression
  9. Pregnancy and MS - DMT safety, relapse risk postpartum
  10. Prognosis - poor prognostic factors, disability progression (EDSS)

Brief overview

MS is a chronic autoimmune, inflammatory demyelinating disease of the central nervous system (brain, spinal cord, optic nerves), typically presenting in young adults (20-40 years) with a strong female predominance (about 2-3:1). It's driven by autoreactive T and B cells attacking myelin, producing plaques of demyelination and eventual axonal degeneration, visualized classically as periventricular, juxtacortical, infratentorial, and spinal cord lesions on MRI (Bradley and Daroff's Neurology in Clinical Practice).
Most patients (about 85%) present with a relapsing-remitting course - discrete attacks (optic neuritis, sensory disturbance, limb weakness, diplopia, ataxia) followed by partial or complete recovery - which over 10-20 years may transition to secondary progressive MS with steady decline. A smaller subset has primary progressive MS from onset without distinct relapses.
Diagnosis relies on the McDonald criteria, combining clinical attacks with MRI evidence of lesions disseminated in space and time, supported by CSF oligoclonal bands. Management has two pillars: disease-modifying therapies to reduce relapse rate and slow progression (ranging from injectable interferons/glatiramer acetate to high-efficacy monoclonal antibodies like ocrelizumab and natalizumab), and symptomatic treatment for spasticity, fatigue, bladder dysfunction, and mood.
Recent systematic reviews (2024-2025) have looked at combination DMT therapy versus monotherapy (PMID: 40761068) and non-pharmacologic approaches like hypnotherapy for fatigue (PMID: 40505709) - these could be worth checking if you're interested in current evidence updates.
Which of these would you like me to go deep on?
Asking for Preferences

Which aspect of multiple sclerosis would you like to explore in detail?

This is a shared conversation. Sign in to Orris to start your own chat.